Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) dropped 3.7% during trading on Monday . The company traded as low as $14.05 and last traded at $14.41, with a volume of 305,583 shares trading hands. The stock had previously closed at $14.96.

BLCM has been the topic of a number of analyst reports. SunTrust Banks Inc. initiated coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 price target on the stock. Zacks Investment Research lowered Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 17th. Jefferies Group reduced their price target on Bellicum Pharmacueticals from $35.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, March 15th. Finally, Piper Jaffray Cos. reduced their price target on Bellicum Pharmacueticals from $45.00 to $33.00 in a research report on Tuesday, March 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $28.00.

The firm’s market cap is $383.98 million. The company’s 50 day moving average is $12.53 and its 200 day moving average is $11.60.

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.07. Equities research analysts forecast that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current year.

In other news, VP Ken Moseley sold 15,000 shares of Bellicum Pharmacueticals stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total value of $195,000.00. Following the transaction, the vice president now owns 15,196 shares in the company, valued at $197,548. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CTO Kevin M. Slawin sold 55,000 shares of Bellicum Pharmacueticals stock in a transaction dated Friday, April 22nd. The stock was sold at an average price of $11.43, for a total value of $628,650.00. Following the completion of the transaction, the chief technology officer now owns 159,206 shares in the company, valued at approximately $1,819,724.58. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley increased its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent SEC filing.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.